Close Menu

NEW YORK – Nestlé Health Science has closed the sale of Prometheus Laboratories — a US-based subsidiary — to Precision IBD, a biopharmaceutical company focused on the discovery and development of precision therapeutics and companion diagnostics for inflammatory bowel diseases.

The sale of San Diego, California-based Prometheus, a developer of pharmaceutical and diagnostic products with a focus on gastrointestinal diseases, became effective June 30. Financial and other terms of the deal were not disclosed.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.